中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
A novel BODIPY-based theranostic agent for in vivo fluorescence imaging of cerebral Aβ and ameliorating Aβ-associated disorders in Alzheimer's disease transgenic mice

文献类型：期刊论文

作者Zhang, Jingjing3,4,5; Ren, Wenming4,5; Liu, Xiaohui3,5; Chen, Jingjing2; Zeng, Yuteng1,5; Xiang, Huaijiang3,5; Hu, Youhong2,3,5; Zhang, Haiyan3,4,5
刊名RSC MEDICINAL CHEMISTRY
出版日期2024-03-15
页码9
DOI10.1039/d3md00744h
通讯作者Hu, Youhong(yhhu@simm.ac.cn) ; Zhang, Haiyan(hzhang@simm.ac.cn)
英文摘要beta-Amyloid (A beta) aggregation is increasingly recognized as both a biomarker and an inducer of the progression of Alzheimer's disease (AD). Here, we describe a novel fluorescent probe P14, developed based on the BODIPY structure, capable of simultaneous visualization and inhibition of A beta aggregation in vivo. P14 shows high binding affinity to A beta aggregates and selectively labels A beta plaques in the brain slices of APP/PS1 mice. Moreover, P14 is able to visualize overloaded A beta in both APP/PS1 and 5 x FAD transgenic mice in vivo. From the aspect of potential therapeutic effects, P14 administration inhibits A beta aggregation and alleviates A beta-induced neuronal damage in vitro, as well as reduces central A beta deposition and ameliorates cognitive impairment in APP/PS1 transgenic mice in vivo. Finally, P14 is applied to monitor the progression of A beta aggregation in the brain of 5 x FAD transgenic mice and the intervention effect itself by fluorescence imaging. In summary, the discovery of this fluorescent agent might provide important clues for the future development of theranostic drug candidates targeting A beta aggregation in AD.
WOS关键词AMYLOID-BETA ; GLUTAMATE RELEASE ; PROBE ; PLAQUES ; LIGHT
资助项目China Postdoctoral Science Foundation[2021ZD0200900] ; National Science and Technology Innovation 2030 Major Program[82003724] ; National Natural Science Foundation of China[2019M661669] ; China Postdoctoral Science Foundation[2018ZX09711002] ; National S&T Major Projects[2018SHZDZXO5] ; Shanghai Municipal Science and Technology Major Project
WOS研究方向Biochemistry & Molecular Biology ; Pharmacology & Pharmacy
语种英语
WOS记录号WOS:001185498000001
出版者ROYAL SOC CHEMISTRY
源URL[http://119.78.100.183/handle/2S10ELR8/310133]  
专题新药研究国家重点实验室
通讯作者Hu, Youhong; Zhang, Haiyan
作者单位1.ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China
2.UCAS, Hangzhou Inst Adv Study, Sch Pharmaceut Sci & Technol, 1 Xiangshanzhi Rd, Hangzhou 310024, Peoples R China
3.Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China
4.Chinese Acad Sci, CAS Key Lab Receptor Res, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
5.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714		 Zhang, Jingjing,Ren, Wenming,Liu, Xiaohui,et al. A novel BODIPY-based theranostic agent for in vivo fluorescence imaging of cerebral Aβ and ameliorating Aβ-associated disorders in Alzheimer's disease transgenic mice[J]. RSC MEDICINAL CHEMISTRY,2024:9.
APA Zhang, Jingjing.,Ren, Wenming.,Liu, Xiaohui.,Chen, Jingjing.,Zeng, Yuteng.,...&Zhang, Haiyan.(2024).A novel BODIPY-based theranostic agent for in vivo fluorescence imaging of cerebral Aβ and ameliorating Aβ-associated disorders in Alzheimer's disease transgenic mice.RSC MEDICINAL CHEMISTRY,9.
MLA Zhang, Jingjing,et al."A novel BODIPY-based theranostic agent for in vivo fluorescence imaging of cerebral Aβ and ameliorating Aβ-associated disorders in Alzheimer's disease transgenic mice".RSC MEDICINAL CHEMISTRY (2024):9.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。